Muhammad Saleem received his PhD in “Biomolecular Sciences” from The University of Manchester, UK, in 2008. From 2013 to 2015, he worked for eukaryotic expression of human blood clotting factors at Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds. He then joined as a Post-Doctoral Research scientist in the Division of Medicinal Chemistry and Structural Biology at the Centre for Biomolecular Sciences (CBS), School of Pharmacy, The University of Nottingham, UK, to study the novel mechanism of thrombosis. In September 2017, he moved to the Laboratory of Nanomedicine at King Abdullah University of Science and Technology, Saudi Arabia, to work on the impact of aggregation-triggering motifs on the solubility of proteins and viral vaccine research. Later, he started working at the Biodiscovery Institute, BDI, The University of Nottingham, UK, to study the structure of membrane proteins involved in Quorum sensing. His research interests include 1. prokaryotic and eukaryotic expression of recombinant therapeutic proteins, 2. production of membrane protein and their complexes (special focus on ABC transporters), 3. structural and functional characterization of proteins, 4. recombinant vaccine development, and 5. rational design, synthesis and understanding of peptide-based nanomaterials for biomedical applications.
Muhammad Saleem received his PhD in “Biomolecular Sciences” from The University of Manchester, UK, in 2008. From 2013 to 2015, he worked for eukaryotic expression of human blood clotting factors at Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds. He then joined as a Post-Doctoral Research scientist in the Division of Medicinal Chemistry and Structural Biology at the Centre for Biomolecular Sciences (CBS), School of Pharmacy, The University of Nottingham, UK, to study the novel mechanism of thrombosis. In September 2017, he moved to the Laboratory of Nanomedicine at King Abdullah University of Science and Technology, Saudi Arabia, to work on the impact of aggregation-triggering motifs on the solubility of proteins and viral vaccine research. Later, he started working at the Biodiscovery Institute, BDI, The University of Nottingham, UK, to study the structure of membrane proteins involved in Quorum sensing. His research interests include 1. prokaryotic and eukaryotic expression of recombinant therapeutic proteins, 2. production of membrane protein and their complexes (special focus on ABC transporters), 3. structural and functional characterization of proteins, 4. recombinant vaccine development, and 5. rational design, synthesis and understanding of peptide-based nanomaterials for biomedical applications.